H.C. Wainwright analyst Arthur He downgraded Adaptimmune (ADAP) to Neutral from Buy without a price target after the company agreed to sell Tecelra, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for up to $85M. With only preclinical assets remaining in the pipeline, Adaptimmune has now meaningful near-term catalysts, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Sells Cell Therapy Assets to US WorldMeds
- Adaptimmune Settles Litigation with M.D. Anderson Cancer Center
- General Mills upgraded, Trade Desk downgraded: Wall Street’s top analyst calls
- Mizuho downgrades Adaptimmune to Neutral on solvency concerns
- Adaptimmune downgraded to Neutral from Outperform at Mizuho